Sanofi’s $3.2 Billion Acquisition of Translate Bio

Weil, Gotshal & Manges acted as legal counsel to Sanofi, while Paul, Weiss, Rifkind, Wharton & Garrison acted as legal counsel to Translate Bio. Skadden, Arps, Slate, Meagher & Flom advised Centerview Partners on the deal.

Translate Bio entered into a definitive agreement with Sanofi, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully diluted basis). The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.

Centerview Partners acted as lead financial advisor to Translate Bio in the transaction.

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity.

Sanofi is dedicated to supporting people through their health challenges. Sanofi is a global biopharmaceutical company focused on human health. It prevents illness with vaccines, provides innovative treatments to fight pain and ease suffering.

The Skadden team included M&A partners Marie Gibson (New York) and Graham Robinson (Boston), and associate Jonny Gelfand (New York).

The Weil team advising Sanofi was led by Mergers & Acquisitions partner Michael J. Aiello and included Mergers & Acquisitions partner Matthew Gilroy and Mergers & Acquisitions associates Iliana Ivanova, Daniel Sotsky and Emily Ross. The team also included Tax partner Graham Magill; Tax associate Charles Kogel; Executive Compensation & Benefits Head Paul Wessel; Executive Compensation & Benefits counsel Steven Margolis; Executive Compensation & Benefits associate Robin Caskey; Technology & IP Transactions Head Michael Epstein; Technology & IP Transactions associates Lauren Springer, Maryann Thompson and Alex Theuer (Not Yet Admitted in New York); Regulatory Transactions partner Shawn Cooley; Regulatory Transactions counsel John O’Loughlin; Regulatory Transactions associate Nathan Cunningham; Antitrust partner John Scribner; Antitrust counsel Michael Naughton; and Antitrust associate Vivian Wang.

Involved fees earner: Jonny Gelfand – Skadden Arps Slate Meager & Flom; Marie Gibson – Skadden Arps Slate Meager & Flom; Graham Robinson – Skadden Arps Slate Meager & Flom; Michael Aiello – Weil, Gotshal & Manges; Robin Caskey – Weil, Gotshal & Manges; Shawn Cooley – Weil, Gotshal & Manges; Nathan Cunningham – Weil, Gotshal & Manges; Michael Epstein – Weil, Gotshal & Manges; Matthew Gilroy – Weil, Gotshal & Manges; Iliana Ivanova – Weil, Gotshal & Manges; Charles Kogel – Weil, Gotshal & Manges; Graham Magill – Weil, Gotshal & Manges; Steven Margolis – Weil, Gotshal & Manges; Michael Naughton – Weil, Gotshal & Manges; John O’Loughlin – Weil, Gotshal & Manges; Emily Ross – Weil, Gotshal & Manges; John Scribner – Weil, Gotshal & Manges; Daniel Sotsky – Weil, Gotshal & Manges; Lauren Springer – Weil, Gotshal & Manges; Maryann Thompson – Weil, Gotshal & Manges; Vivian Wang – Weil, Gotshal & Manges; Paul Wessel – Weil, Gotshal & Manges;

Law Firms: Skadden Arps Slate Meager & Flom; Weil, Gotshal & Manges;

Clients: Centerview Partners; Sanofi S.A.;

Martina Bellini

Author: Martina Bellini